Novo Nordisk reported DKK42.77B in Operating Expenses for its fiscal quarter ending in June of 2025.





Operating Expenses Change Date
Bausch Health Companies USD 1.96B 109M Sep/2025
Bristol-Myers Squibb USD 18.55B 10.06B Sep/2025
Eli Lilly USD 9.21B 677.8M Sep/2025
GlaxoSmithKline GBP 5.76B 203M Sep/2025
Merck USD 10.72B 1.28B Sep/2025
Novartis USD 9.86B 115M Sep/2025
Novo Nordisk DKK 42.77B 3.48B Jun/2025
Novo Nordisk DKK 6.5B 32.8B Jun/2025
Pacira USD 166.36M 4.5M Sep/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Supernus Pharmaceuticals USD 252.29M 98.98M Sep/2025